Clinical Efficacy of MOAP Regimen for Relapsed/Refractory cHL as a Rescue Therapy After DP Regimen
Status:
Unknown status
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
The DP regimen, low-dose decitabine combined with SHR-1210, is the new treatment for relapsed
or refractory classical Hodgkin's Lymphoma. Though the CR rate of this regimen is
impressively high, which is verified more than 70% in our I/II phase study, there are also
lots of patients cannot benefit from this treatment. On top of that, as the increasing
utilization of mono-therapy or combination treatment with the immune checkpoint blockade
(ICB), the adverse reactions associated with immunotherapy make it unavailable in parts of
patients. The application of MOAP regimen to patients, who have a progressive disease after
DP regimen, can bring high CR rate. MOAP can be the a rescue treatment for cHL resisted to DP
treatment.